Simulations Plus 2021

“For Biotech companies, finding strategic partnerships is a necessity in streamlining our development programs to save time and money. Simulations Plus nimbly partnered on a program to not only develop a PBPK model, but to also develop a DDI regulatory roadmap that informed our regulatory approach towards NDA filing and helped to design the next steps of our program. Their knowledge of the area and ease of partnering exceeded my expectations.”

Sr. Vice President, Pharmaceutical Sciences
“I’d like to give some feedback regarding the excellent prediction work that you performed previously. We have received the results from the clinical phase 1b cohort now and have been able to compare the test item concentrations to those predicted in the model that you created. The predictions are really amazingly accurate!”
Head of Nonclinical Development
“Just wanted to drop a quick note and take the opportunity to highlight the excellent software application support the team has provided for GastroPlus. I really don’t think I would have got to where we have on my own but feel much better positioned now to use some of these additional features in the software. The team has excellent customer focus, and I really like the style and manner in which you interact with the user.”
Lead Specialist
“Often clients are fast and furious to send complaint notes to the CRO, but silent when things are going well. Good work equally needs appreciation & recognition. I am pleased to tell you that I am very happy with the progress of our project at Simulations Plus.”
Sr. Director, Translational Drug Development
November 3, 2022
2022 Employee Highlights

2022 Employee Highlights

  • Gustavo Mendez Lima Santos Joins Simulations Plus (Formerly Anvisa, Brazil) (11/3/22)
  • Renée Bouché celebrates 21 years at Simulations Plus (10/29/22)
  • Frederico Martins Joins Simulations Plus (Formerly esqLABS, Galapagos Pharmaceuticals, Certara) (10/24/22)
  • Xavier Pepin Joins Simulations Plus (Formerly AstraZeneca & Sanofi) (5/2/22)
  • Anant Ketkar Joins Simulations Plus (Formerly IQGEN-X Pharma, India) (4/11/22)
July 14, 2022
Concierge Program Launched

Concierge Program Launched

Providing one-on-one support for our clients and partners as they navigate the long and winding road of model-informed drug discovery. Learn More

February 16, 2022
2nd Annual MIDD+ 2022 Virtual Conference

2nd Annual MIDD+ 2022 Virtual Conference

Improving Health Through Innovative Solutions in Model-Based Drug Discovery. Watch Session Replays

November 30, 2021
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope

Expanding access to high-quality medication for people in need Read More

November 18, 2021
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference

Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference

Yo-Yo dieting without additional treatment can explain high placebo response rates in NASH clinical trials. Read More

October 21, 2021
Simulations Plus Announces the University+ Program

Simulations Plus Announces the University+ Program

Free access to Simulations Plus software for accredited universities will accelerate learning and educational pursuits. Learn More

July 8, 2021
Simulations Plus Celebrates 25 Years in Business

Simulations Plus Celebrates 25 Years in Business

“We are very proud and humbled by our achievements at SLP over these past 25 years and look forward to celebrating this milestone over the next year with our clients, employees, and collaborators,” said Shawn O’Connor, CEO. Learn More

May 12, 2021
Simulations Plus Uplisted to The Nasdaq Global Select Market®

Simulations Plus Uplisted to The Nasdaq Global Select Market®

Strong growth, innovation, and global reach drive the company’s progress. Read More

March 3, 2021
Hosts The Inaugural 2021 MIDD+ Scientific Conference

Hosts The Inaugural 2021 MIDD+ Scientific Conference

Simulations Plus hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions. Read More

September 15, 2020
Releases ADMET Predictor® Version 10.0 (APX™)

Releases ADMET Predictor® Version 10.0 (APX™)

Simulations Plus released version 10.0 of its flagship machine learning modeling platform, ADMET Predictor®, The new release is marketed as APX™ on September 2020. Read More

August 10, 2020
Simulations Plus Raised About $115 Million Underwritten Public Offering of Common Stock

Simulations Plus Raised About $115 Million Underwritten Public Offering of Common Stock

Simulations Plus announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share. Learn More

April 1, 2020
Lixoft becomes a subsidiary of Simulations Plus

Lixoft becomes a subsidiary of Simulations Plus

Lixoft becomes a wholly owned subsidiary of Simulations Plus on April, 2020. Lixoft is design software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. Learn More

January 6, 2020
Grace Fraczkiewicz Celebrates 20 Years of Service

Grace Fraczkiewicz Celebrates 20 Years of Service

In January 2020, Grace Fraczkiewicz celebrated her 20 years of service with Simulations Plus. Read About Her Journey

August 6, 2018
Robert Fraczkiewicz Celebrates 20 Years of Service

Robert Fraczkiewicz Celebrates 20 Years of Service

In August of 2018, Robert Fraczkiewicz celebrated his 20 years of service with Simulations Plus. Read About His Journey

June 26, 2018
Simulations Plus Names Shawn O’Connor as CEO

Simulations Plus Names Shawn O’Connor as CEO

Shawn M. O’Connor appointed as Chief Executive Officer(CEO) effective from June 26, 2018. Learn More

February 1, 2018
S+pKa Model Wins SAMPL6 pKa Challenge

S+pKa Model Wins SAMPL6 pKa Challenge

Predictions of ionization constants performed by the S+pKa method implemented in ADMET Predictor™ software wins SAMPL6 pKa challenge on February 2018. Learn More

June 1, 2017
DILIsym Services, Inc. Becomes a Subsidiary of Simulations Plus

DILIsym Services, Inc. Becomes a Subsidiary of Simulations Plus

DILIsym becomes a wholly owned subsidiary of Simulations Plus. DILIsym is the global leader in the simulation of drug-induced liver injury (“DILI”). Learn More

October 10, 2016
Jill Fiedler-Kelly Named Fellow of ISoP

Jill Fiedler-Kelly Named Fellow of ISoP

Jill Fiedler-Kelly awarded with ISoP Fellowship for her professional excellence and superior impact in pharmacometrics, and for substantial volunteering work for ISoP on October, 2016. Learn More

August 25, 2016
Simulations Plus Releases PKPlus™ Version 1.0

Simulations Plus Releases PKPlus™ Version 1.0

Simulations Plus released version 1.0 of PKPlus™, its next-generation software for analysis of preclinical and clinical trial data. Learn More

December 9, 2014
First Commercial Simulx Version

First Commercial Simulx Version

Lixoft released version 1.0 of Simulx, an easy, efficient and flexible application for clinical trail simulations, on December 2014. Learn More

October 21, 2014
MembranePlus™ Version 1.0 Released

MembranePlus™ Version 1.0 Released

Simulations Plus announced that it has expanded its product portfolio with the release of version 1.0 of its MembranePlus™ simulation software on October 2014. Learn More

September 2, 2014
Cognigen Corporation Becomes a Subsidiary of Simulations Plus

Cognigen Corporation Becomes a Subsidiary of Simulations Plus

Cognigen became a wholly-owned subsidiary of Simulations Plus on September 2014. Learn More

July 7, 2014
Joel and Jill published “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models”

Joel and Jill published “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models”

Joel S. Owen and Jill Fiedler-Kelly published a textbook on “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models” on July 2014. Read More

March 4, 2013
Ted Grasela Awarded With The Gary Neil Prize from ASCPT

Ted Grasela Awarded With The Gary Neil Prize from ASCPT

Dr. Grasela was awarded the Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology and Therapeutics(ASCPT). Learn More

January 9, 2012
DILIsym® Version 1A Released

DILIsym® Version 1A Released

DILIsym® Version 1A was released on January 2012. Learn More

October 3, 2011
First commercial Monolix® Version 1.0

First commercial Monolix® Version 1.0

Monolix® Version 1.0 was released on October 2011. Learn More

July 7, 2009
Simulations Plus Named to Fortune Small Business FSB 100 List

Simulations Plus Named to Fortune Small Business FSB 100 List

Simulations Plus has been named to the ninth annual Fortune Small Business FSB 100 list of the fastest-growing small public companies in America. Learn More

February 9, 2005
DDDPlus™ 1.0 Released

DDDPlus™ 1.0 Released

Simulations Plus released version 1.0 of DDDPlus™, a simulation of in vitro dissolution experiments for formulation scientists in the pharmaceutical industry on February 2005. Learn More

January 4, 2005
ADMET Predictor™ 1.0 Released

ADMET Predictor™ 1.0 Released

Simulations Plus released version 1.0 of ADMET Predictor™, formerly known as QMPRPlus™ on January 2005. Learn More

July 1, 1999
Simulations Plus Listed on The NASDAQ

Simulations Plus Listed on The NASDAQ

In 1999, Simulations Plus listed on the NASDAQ (American Stock Exchange) under the symbol SLP.

July 1, 1998
GastroPlus® Version 1.0 Released

GastroPlus® Version 1.0 Released

Simulations Plus releases its flagship PBPK modeling and simulation, GastroPlus®, in July 1998. Learn More

July 1, 1996
Simulations Plus Incorporated in Lancaster, California

Simulations Plus Incorporated in Lancaster, California

Simulations Plus incorporated in Lancaster, California in July 1996.